Related Experiment Video

Updated: Jul 6, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a

Manju Mamtani1, Hemant Kulkarni

  • 1Lata Medical Research Foundation, Nagpur, India.

British Journal of Haematology
|March 22, 2008
PubMed

Insights

Iron chelators effectively reduce cardiac iron in thalassemia patients, but do not significantly improve heart function (left ventricular ejection fraction). The choice between deferoxamine and deferiprone may depend on factors beyond iron reduction efficacy.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Transfusion-dependent thalassemia leads to iron overload, primarily affecting the heart.
  • Iron chelators improve life expectancy but their cardiac benefits require clarification.

Purpose of the Study:

  • To systematically review and meta-analyze the clinical efficacy of iron chelators in reducing myocardial iron burden and improving cardiac function in thalassemia major patients.

Main Methods:

  • Systematic review and meta-analysis of published clinical trials.
  • Included regularly transfused thalassemia major patients.
  • Assessed myocardial iron content and left ventricular ejection fraction (LVEF).

Main Results:

  • Iron chelators reduced myocardial iron content by 23.9% (CI 17.3-29.8%).
  • No significant difference in iron reduction between deferoxamine and deferiprone (P=0.9504).
  • LVEF was not significantly influenced by iron chelators (Hedge's g=0.13, CI -0.10-0.36).
  • Publication bias was noted for LVEF but not myocardial iron.

Conclusions:

  • Iron chelators significantly reduce myocardial iron content in transfusion-dependent thalassemia.
  • Current evidence does not support a significant impact of iron chelators on LVEF.
  • Treatment choice between deferoxamine and deferiprone may not be based on cardiac iron reduction efficacy.

More Related Videos

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron05:36

Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron

Published on: February 23, 2024

Related Concept Videos

The Early Endosome: Endocytosis of Transferrin01:28

The Early Endosome: Endocytosis of Transferrin

Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...